Lack of miR-378 attenuates muscular dystrophy in mdx mice
Article 2020 en
Authors
PP
Paulina Podkalicka
OM
Olga Mucha
IB
Iwona Bronisz-Budzyńska
Abstract
1 min read
The severity of Duchenne muscular dystrophy (DMD), an incurable disease caused by the lack of dystrophin, might be modulated by different factors, including miRNAs. Among them, miR-378 is considered of high importance for muscle biology, but intriguingly, its role in DMD and its murine model (mdx mice) has not been thoroughly addressed so far. Here, we demonstrate that dystrophic mice additionally globally lacking miR-378 (double-KO [dKO] animals) exhibited better physical performance and improved absolute muscle force compared with mdx mice. Accordingly, markers of muscle damage in serum were significantly decreased in dKO mice, accompanied by diminished inflammation, fibrosis, and reduced abundance of regenerating fibers within muscles. The lack of miR-378 also normalized the aggravated fusion of dystrophin-deficient muscle satellite cells (mSCs). RNA sequencing of gastrocnemius muscle transcriptome revealed fibroblast growth factor 1 (Fgf1) as one of the most significantly downregulated genes in mice devoid of miR-378, indicating FGF1 as one of the mediators of changes driven by the lack of miR-378. In conclusion, we suggest that targeting miR-378 has the potential to ameliorate DMD pathology.
Paulina Podkalicka, Olga Mucha, Katarzyna Kaziród, Krzysztof Szade, Jacek Stępniewski, Liudmyla Ivanishchuk, Hirofumi Hirao, Ewelina Pośpiech, Alicja Józkowicz, Jerzy W. Kupiec‐Weglinski, Jozef Dulak, Agnieszka Łoboda
Mònica Suelves, Berta Vidal, Antonio L. Serrano, Marc Tjwa, Josep Roma, Roser López‐Alemany, Aernout Luttun, María Martínez de Lagrán, Maria Àngels Díaz, Mercè Jardı́, Manuel G. Roig, Mara Dierssen, Mieke Dewerchin, Peter Carmeliet, Pura Muñoz‐Cánoves
Paulina Podkalicka, Olga Mucha, Katarzyna Kaziród, Iwona Bronisz-Budzyńska, Sophie Ostrowska-Paton, Mateusz Tomczyk, Kalina Andrysiak, Jacek Stępniewski, Jozef Dulak, Agnieszka Łoboda
Discussion(0)
No comments yet. Be the first to comment.